Enoblituzumab ELISA Kit
- Catalog number: EL10154
- Availability: In Stock
$1,126.00
- Ex Tax: $1,126.00
- Stability and Storage: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
- Detection method: Colorimetric
- Sample type: Plasma, Serum
- Assay type: Quantitative
- Sensitivity: 0.156 μg/ml
- Range: 0.31-5 μg/mL
- Recovery: 80-120%
- Background: Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.
- Alternative Names: MG-A271, , CAS: 1353485-38-7
- Shipping: 2-8 ℃
- Specifications: Enoblituzumab
- Note: For Research Use Only.
Image Data
No validation image data is currently available for this product.
Datasheet
